Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of EUR 110.75 billion. The enterprise value is 126.56 billion.

Market Cap	110.75B
Enterprise Value	126.56B

Important Dates

The next estimated earnings date is Monday, February 3, 2025.

Earnings Date	Feb 3, 2025
Ex-Dividend Date	Dec 13, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.91%
Shares Change (QoQ)	+0.24%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.24B

Valuation Ratios

The trailing PE ratio is 980.35.

PE Ratio	980.35
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.34, with an EV/FCF ratio of 14.97.

EV / Earnings	1,120.29
EV / Sales	4.66
EV / EBITDA	9.34
EV / EBIT	11.78
EV / FCF	14.97

Financial Position

The company has a current ratio of 1.26, with a Debt / Equity ratio of 1.26.

Current Ratio	1.26
Quick Ratio	0.96
Debt / Equity	1.26
Debt / EBITDA	1.65
Debt / FCF	2.47
Interest Coverage	11.42

Financial Efficiency

Return on equity (ROE) is 0.56% and return on invested capital (ROIC) is 15.74%.

Return on Equity (ROE)	0.56%
Return on Assets (ROA)	11.96%
Return on Capital (ROIC)	15.74%
Revenue Per Employee	1.41M
Profits Per Employee	6,276
Employee Count	18,000
Asset Turnover	0.48
Inventory Turnover	3.56

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +22.51% in the last 52 weeks. The beta is 0.20, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.20
52-Week Price Change	+22.51%
50-Day Moving Average	85.36
200-Day Moving Average	71.23
Relative Strength Index (RSI)	56.51
Average Volume (20 Days)	1,949

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.50

Income Statement

In the last 12 months, Gilead Sciences had revenue of EUR 25.37 billion and earned 112.97 million in profits. Earnings per share was 0.09.

Revenue	25.37B
Gross Profit	19.74B
Operating Income	10.03B
Pretax Income	158.70M
Net Income	112.97M
EBITDA	12.51B
EBIT	10.03B
Earnings Per Share (EPS)	0.09

Full Income Statement

Balance Sheet

The company has 6.00 billion in cash and 20.85 billion in debt, giving a net cash position of -14.84 billion.

Cash & Cash Equivalents	6.00B
Total Debt	20.85B
Net Cash	-14.84B
Net Cash Per Share	n/a
Equity (Book Value)	16.49B
Book Value Per Share	13.29
Working Capital	2.74B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.99 billion and capital expenditures -529.89 million, giving a free cash flow of 8.46 billion.

Operating Cash Flow	8.99B
Capital Expenditures	-529.89M
Free Cash Flow	8.46B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 77.80%, with operating and profit margins of 39.53% and 0.45%.

Gross Margin	77.80%
Operating Margin	39.53%
Pretax Margin	0.63%
Profit Margin	0.45%
EBITDA Margin	49.29%
EBIT Margin	39.53%
FCF Margin	33.33%

Dividends & Yields

This stock pays an annual dividend of 2.85, which amounts to a dividend yield of 3.21%.

Dividend Per Share	2.85
Dividend Yield	3.21%
Dividend Growth (YoY)	2.30%
Years of Dividend Growth	9
Payout Ratio	3,085.71%
Buyback Yield	0.91%
Shareholder Yield	4.12%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on January 28, 2013. It was a forward split with a ratio of 2.

Last Split Date	Jan 28, 2013
Split Type	Forward
Split Ratio	2

Scores

Gilead Sciences has an Altman Z-Score of 3.09.

Altman Z-Score	3.09
Piotroski F-Score	n/a